A multicenter, randomized, partially blinded, placebo-controlled clinical trial to evaluate the effect on primary dysmenorrheal of vaginal rings with an average daily release of 700 µg nomegestrol acetate (NOMAC) and 300 µg estradiol (E2), or 900 µg nomegestrol acetate (NOMAC) and 300 µg estradiol (E2), or 100 µg etonogestrel (ENG) and 300 µg E2, or 125 µg etonogestrel (ENG) and 300 µg E2
- Conditions
- primaire dysmenorroe + reproductive system and breast disorders (menstrual cycle and uterine bleeding disorders)pain and/or cramps during menstruation
- Registration Number
- NL-OMON36928
- Lead Sponsor
- Merck Sharp & Dohme (MSD)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 35
1. Subject must be willing and able to provide written informed consent for the trial.
2. Subject must be female.
3. Subject must be >=18 to <= 50 years of age.
4. Subject must have a body mass index (BMI) >=18 and <=35.
5. Subject must have an established diagnosis of primary dysmenorrhea, characterized by menstrual pain in the absence of detectable pelvic pathology (eg, endometriosis, fibroids, pelvic inflammatory disease).
6. Each non-sterilized sexually active subject of child-bearing potential must agree to use condoms for contraception during the entire screening period, treatment period, and post-treatment period until the final study visit.
7. Subject using a hormonal contraceptive (combined or progestin-only), or a non-hormonal IUD, at the screening visit must agree to stop using that method.
8. Subject has regular menstrual cycles ranging from 24 to 32 days in length (to be confirmed at the randomization visit following completion of a baseline menstrual cycle).
1. Subject has any contraindication to the use of contraceptive steroids.
2. Subject has secondary dysmenorrhea - ie, menstrual pain in the presence of detectable pelvic pathology (eg, endometriosis, fibroids, pelvic inflammatory disease).
3. Subject has not had spontaneous menstruation following a delivery or abortion at the screening visit.
4. The subject is breastfeeding or has not had spontaneous menstruation following completion of breastfeeding at the screening visit.
5. Subject has a history of malignancy <=5 years prior to signing the informed consent, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer.
6. Subject had a documented abnormal cervical smear result within 6 months prior to the screening visit.
7. Subject routinely consumes >2 alcoholic drinks per day or >14 alcoholic drinks per week, or engages in binge drinking.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The Primary Efficacy Endpoint is the change in menstrual cramping score based<br /><br>on item #10 of the MDQ from baseline to the second in-treatment intended<br /><br>bleeding episode.<br /><br>The Primary Efficacy Endpoint is related to the Primary Trial Objective. </p><br>
- Secondary Outcome Measures
Name Time Method <p>The secondary efficacy endpoints are calculated from baseline through the<br /><br>second in-treatment intended bleeding episode and concern:<br /><br>• total mean impact score from baseline through the second in-treatment<br /><br>intended bleeding episode (total mean impact score is defined as the mean of<br /><br>the sum of daily responses to questions 5, 7, 8, and 9 in the DysDD)<br /><br>• total number of tablets of ibuprofen taken<br /><br>• number of days of intake of ibuprofen<br /><br>Secondary efficacy endpoints will be analyzed in the same manner as the primary<br /><br>variable.</p><br>